A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TLM / thiolactomycin

[Related PubMed/MEDLINE]
Total Number of Papers: 26
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TLM  (>> Co-occurring Abbreviation)
Long Form:   thiolactomycin
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Anti-Tubercular Properties of 4-Amino-5-(4-Fluoro-3- Phenoxyphenyl)-4H-1,2,4-Triazole-3-Thiol and Its Schiff Bases: Computational Input and Molecular Dynamics. KasA, MDR, Mtb, REMA
2018 Design, Synthesis and Biological Evaluation of Some Triazole Schiff's Base Derivatives as Potential Antitubercular Agents. TB
2017 Minimization of the Thiolactomycin Biosynthetic Pathway Reveals that the Cytochrome P450 Enzyme TlmF Is Required for Five-Membered Thiolactone Ring Formation. BGC
2016 A genomics-led approach to deciphering the mechanism of thiotetronate antibiotic biosynthesis. ---
2016 Thiolactomycin-Based Inhibitors of Bacterial beta-Ketoacyl-ACP Synthases with in Vivo Activity. FAS II, KAS, MRSA
2013 Thiolactomycin-based beta-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. KasA
2010 3D-QSAR, molecular docking studies, and binding mode prediction of thiolactomycin analogs as mtFabH inhibitors. 3D-QSAR, CoMFA, CoMSIA
2010 Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin. KAS
2010 Thiolactomycin inhibits D-aspartate oxidase: a novel approach to probing the active site environment. DAO, DDO, FAD
10  2009 Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH. TB
11  2009 Synthesis and biological activity of enantiomeric pairs of 5-(Alk-2-enyl)thiolactomycin and 5-[(E)-Cycloalk-2-enylidenemethyl]thiolactomycin congeners. FAS
12  2009 Thiolactomycin analogues as potential anti-Toxoplasma gondii agents. ---
13  2007 X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB). ACP, FAS, mtKasB
14  2005 Analogues of thiolactomycin as potential antimalarial agents. ---
15  2005 Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. FAS
16  2004 Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents. ---
17  2003 Biosynthetic origins of the natural product, thiolactomycin: a unique and selective inhibitor of type II dissociated fatty acid synthases. ---
18  2002 A missense mutation in the fabB (beta-ketoacyl-acyl carrier protein synthase I) gene confers tiolactomycin resistance to Escherichia coli. ---
19  2002 Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. ---
20  2002 Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. ETH
21  2001 Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. ACP
22  2000 Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. ACP, FAS, Mtb, TRC
23  2000 Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. ---
24  1996 Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. FAS I
25  1993 Thiolactomycin resistance in Escherichia coli is associated with the multidrug resistance efflux pump encoded by emrAB. ---
26  1990 Antimicrobial activities of thiolactomycin against gram-negative anaerobes associated with periodontal disease. f1. ---